Medifast director Parsa Kiai acquires $842,698 in company shares By Investing.com
Medifast director Parsa Kiai indirectly acquired shares worth $842,698 on August 19 and 20, 2026, through investment entities he manages. The acquisitions occurred at average prices between $11.6037 and $11.6576 per share, with the company's stock currently trading at $11.95. Despite Medifast's impressive gross profit margins, it has not been profitable over the last twelve months, although it recently surpassed analyst expectations for Q2 2026 financial results.
Can Medifast's New Compensation Plan Accelerate Coach Growth?
Medifast has introduced an enhanced compensation plan to strengthen its network of Executive Directors, who are seen as the primary drivers of sustainable business growth. This initiative follows a significant decline in active earning coaches due to GLP-1 medication adoption, though average revenue per coach has increased. The company hopes this new plan, by fostering stronger leadership and improving coach productivity, will lead to future coach and revenue growth.
Medifast (MED): Citadel entities and Kenneth Griffin disclose sub‑5% ownership stake
Citadel entities, including Citadel Securities LLC and Citadel Advisors LLC, along with Kenneth Griffin, have filed an amended Schedule 13G disclosing beneficial ownership of Medifast (MED) common stock. The filing indicates that each reporting person holds less than 5% of Medifast's outstanding shares, with Kenneth Griffin holding the largest individual stake at 2.6%. All reported ownership is based on 11,119,115 shares outstanding as of April 27, 2026, with all reporting persons having shared, rather than sole, voting and dispositive power.
Susquehanna group reports 5.3% Medifast (MED) ownership in Schedule 13G
Susquehanna Portfolio Strategies, LLC and Susquehanna Securities, LLC have collectively reported a 5.3% beneficial ownership stake in Medifast (MED) through a Schedule 13G filing. This amounts to 587,214 shares of Medifast common stock as of June 30, 2026, including options for 542,700 shares held by Susquehanna Securities, LLC. The filing indicates a passive investment purpose, and both entities maintain sole voting and dispositive power over their directly owned shares, with shared power over the total beneficially owned shares.
Medifast (NYSE:MED) Cut to Hold at Zacks Research
Zacks Research downgraded Medifast (NYSE:MED) from "strong buy" to "hold," with Weiss Ratings maintaining a "sell (e+)" rating. The stock has an average "reduce" rating and a consensus price target of $12. Medifast beat earnings and revenue expectations for the last quarter, but still posted negative margins and analysts anticipate a full-year loss.
Can Medifast's Coach Productivity Gains Help Revive Revenue Growth?
Medifast (MED) has seen its revenues stabilize due to increased coach productivity, which rose for the third consecutive quarter in Q2 fiscal 2026. This improvement, with revenue per active earning coach reaching $6,529, suggests a positive trend despite a declining number of active coaches. The company expects continued productivity gains and aims for a return to profitability by Q4 2026, supported by improved client retention and a strategic shift towards metabolic health.
Medifast (MED): Charles Schwab Investment Management reports 3.6% ownership stake
Charles Schwab Investment Management Inc. has reported a 3.6% beneficial ownership stake in Medifast Inc. This amounts to 396,996 shares of common stock, over which Charles Schwab Investment Management Inc. holds sole voting and sole dispositive power. The filing, a Schedule 13G/A, indicates a passive investment intent.
Medifast’s Q2 Earnings Call: Our Top 5 Analyst Questions
Medifast (MED) reported Q2 CY2026 results that exceeded Wall Street expectations for revenue and EPS, driven by improved coach productivity and the new Trilivy brand. The company reconfirmed its full-year revenue guidance and provided positive EPS guidance. Analysts focused on the Catalyst program's cost savings, the path to profitability, coach reception to Trilivy, and future margin trajectory during the earnings call.
Medifast’s Q2 Earnings Call: Our Top 5 Analyst Questions
Medifast's Q2 earnings surpassed analyst expectations, driven by improved coach productivity and the new Trilivy brand. The company reconfirmed its full-year revenue and EPS guidance. Analysts focused on the Catalyst program's costs and profitability impact, coach reception to Trilivy, and future margin trajectory.
MED Rallies 13.6% in the Past Month: Can the Momentum Keep Building?
Medifast (MED) shares have risen 13.6% in the past month, outperforming the industry, driven by narrower-than-expected Q2 2026 losses and improving coach productivity. While revenue and the active coach base remain under pressure, management expects continued productivity gains and has maintained full-year revenue guidance, suggesting potential for sustained momentum despite a mixed operational backdrop.
Can MED's Trilivy Launch and Cost Cuts Drive a Q4 Profit Turnaround?
Medifast (MED) is launching its new Trilivy metabolic-health platform and implementing further cost reductions through its Catalyst program, aiming for a return to profitability in Q4 2026. While Q2 2026 revenues fell year-over-year, they still beat estimates, and coach productivity has shown improvement. The company faces ongoing challenges with shrinking coach numbers and projected losses before Q4, making the turnaround dependent on Trilivy's success, revenue stability, and effective cost savings.
Is MED Worth Buying as Low Valuation Meets a High-Risk Turnaround?
Medifast (MED) presents a challenging investment scenario with a low forward sales valuation compared to its industry, but faces significant headwinds including declining revenues, a shrinking coach network, and ongoing losses. Despite these challenges, the company's strong balance sheet provides a cushion for its Trilivy-led turnaround efforts, which have shown early signs of improved coach productivity. The success of this turnaround hinges on Medifast's ability to drive client acquisition, grow its coach network, and ultimately return to profitability, with management targeting this goal by Q4 2026.
MED Rallies 13.6% in the Past Month: Can the Momentum Keep Building?
Medifast (MED) shares have rallied 13.6% in the past month, outperforming the industry's growth, driven by improving coach productivity and narrowing earnings loss. Despite this, the company still faces challenges with a shrinking coach base and mixed Style Scores, indicating that sustained momentum will depend on continued productivity gains, firmer revenues, and progress toward profitability.
MEDIFAST INC 2026: Revenue $76.38M, EPS ($0.28) — 10-Q Summary
MEDIFAST INC reported its 2026 quarterly results with a significant decline in revenue to $76.38M from $105.56M a year prior, leading to a net loss of ($3.1M) and diluted EPS of ($0.28). This decline was primarily attributed to a roughly 28% drop in active earning coaches. The company launched new initiatives like the Trilivy brand and a new coach compensation plan to improve productivity and retention.
Medifast (MED) Stock Rally Leans On Cash As Coach Base Shrinks
Medifast's stock rallied 34% despite Q2 2026 losses and shrinking revenue, with investors focusing on the company's strong cash position and debt-free balance sheet. Management plans a 10-year metabolic health pivot, aiming to leverage its US$170 million in cash to transition from a declining coach base to a more productive network. While revenue per coach increased, the overall number of coaches and revenue decreased, leading to continued losses, though the company targets profitability by Q4 2026.
Medifast rebrands flagship diet product amid pressure from GLP-1s
Medifast has rebranded its flagship diet program to Trigilvy, signaling an effort to expand its market beyond traditional weight loss. This move comes as the company faces increasing pressure from GLP-1 weight loss drugs. The rebranding is part of the Baltimore company's strategy to adapt to evolving market dynamics and broaden its appeal.
Medifast Inc (MED) (Q2 2026) Earnings Call Highlights: Strategic Pivot to Trilivy and ... By GuruFocus
Medifast Inc. (MED) reported its Q2 2026 earnings, highlighting a strategic pivot to its new Trilivy brand and MetaVantage technology platform to counter declining revenue and active earning coaches. Despite a significant year-over-year revenue decrease of 27.6% and a net loss, the company noted stabilized sequential revenue, increased coach productivity, and a strong balance sheet with no debt. Medifast is implementing a Catalyst program to achieve profitability by Q4 2026, focusing on cost reduction and an enhanced compensation plan for coaches.
Medifast Q2 Loss Narrower Than Expected, Coach Productivity Improves
Medifast (MED) reported a narrower-than-expected Q2 2026 loss of 28 cents per share, surpassing the Zacks Consensus Estimate of a 67-cent loss. Revenues of $76.4 million also slightly exceeded estimates, despite a 27.6% year-over-year decline attributed to a smaller coach network. The company noted improved coach productivity, with average revenue per active earning coach increasing 41% year-over-year, and expects continued improvement in coach productivity and a return to profitability by Q4 2026.
Medifast Q2 Earnings Call Highlights
Medifast (MED) reported a 27.6% year-over-year revenue decline in Q2 2026, reaching $76.4 million, with a net loss of $3.1 million, attributing the decline to a decrease in active earning coaches amidst the rise of GLP-1 medications. Despite the revenue fall, the company noted improved coach productivity and is transitioning its strategy from weight loss to metabolic health, launching the Trilivy brand and the Medifast Metabolic Health Institute. Medifast also introduced a Catalyst cost program and aims for profitability by Q4 2026, maintaining a strong balance sheet with no debt.
Medifast Inc (MED) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Medifast Inc (MED), detailing its current price momentum score, support and resistance levels, and indicator readings. It shows that MED's stock price is currently trading between a resistance level of $10.80 and a support level of $9.03, suggesting suitability for range-bound swing trading. The analysis also includes detailed readings for various technical indicators like MACD, RSI, and moving averages, with a summary indicating a neutral signal based on current metrics.
Medifast’s Active Earning Coaches Fell 48.7% to 11,700 in Q2
Medifast (NYSE: MED) reported a significant decline in its second-quarter 2026 financial results, with revenue falling 27.6% to $76.4 million. The number of active earning coaches decreased by 48.7% to 11,700, primarily due to challenges in client acquisition and the rapid adoption of GLP-1 medications. Despite the revenue drop, the company saw an increase in average revenue per active coach and is implementing a "Catalyst" program for cost savings, aiming for profitability in Q4 2026.
Earnings call transcript: Medifast tops Q2 2026 estimates, shares jump after hours
Medifast reported better-than-expected Q2 2026 results, with a smaller loss and higher revenue than analysts predicted, leading to a 13.96% jump in after-hours trading. The company, facing challenges from GLP-1 medications, is transitioning to a metabolic health focus with its new Trilivy brand and aims for profitability by Q4 2026, supported by improved coach productivity and cost-saving initiatives. Management highlighted the positive reception to Trilivy and the strategic shift towards a comprehensive metabolic health system.
Medifast Inc reports results for the quarter ended June 30 - Earnings Summary
Medifast Inc has released its earnings summary for the quarter that ended on June 30. The full article, originally from Reuters, is available through TradingView, offering unlimited access to subscribers.
Medifast Q2 revenue falls 28% as active coaches drop
Medifast reported a 28% year-over-year decline in Q2 revenue, primarily due to a decrease in active coaches and challenges like the adoption of GLP-1 medications. The company posted a net loss for the quarter, reversing a prior-year profit, despite a 41% rise in revenue per active coach. Medifast provided a cautious outlook for Q3 and full-year 2026, expecting continued revenue decline and net losses.
Medifast Number of Employees 2026 | Employee Count & Headcount Data
Medifast, Inc. (MED) had approximately 381 employees worldwide as of March 2026, according to Revelio Labs data. This represents a 12.3% decline from 434 employees in 2023. The company, headquartered in Baltimore, Maryland, is actively hiring with 12 job postings in 2026, though this is a significant decrease from previous years.
Medifast Inc (MED) Institutional Confidence
Medifast Inc (MED) has an institutional shareholding score of 7.00, placing it 24th out of 93 in the Food & Tobacco industry. The institutional shareholding proportion is 83.21%, a 2.48% decrease quarter-over-quarter. James Simons is the largest institutional shareholder, holding 7.55% of outstanding shares.
Medifast Inc (MED) Q1 2024 Earnings Report - Results, Call & Slides
Medifast Inc (MED) reported its Q1 2024 earnings, missing analyst expectations for EPS with an actual EPS of $0.66 against a consensus of $0.80, a miss of -$0.14. However, the company beat revenue estimates, reporting $174.74M against an expected $173.45M. The revenue for Q1 2024 showed a significant year-over-year decrease of 49.93%.
BlackRock discloses 2.9% Medifast (NYSE: MED) ownership stake
BlackRock, Inc. has reported a beneficial ownership stake of 2.9% in Medifast, Inc. (NYSE: MED), totaling 327,404 shares as of June 30, 2026. The filing, an amended passive investment disclosure (SCHEDULE 13G/A), indicates that BlackRock holds sole voting and dispositive power over these shares, and no single underlying person or client accounts for more than five percent of Medifast's outstanding common shares. This ownership represents 5 percent or less of Medifast's outstanding common stock.
Medifast Stock to Post Q2 Earnings: What Investors Should Know
Medifast (MED) is set to announce its Q2 fiscal 2026 earnings on August 3, with analysts projecting a significant decline in revenue and a loss per share, mainly due to the impact of GLP-1 medications on the weight-loss market. Despite challenges from reduced demand and a shrinking coach network, the company might see some positive impact from improved coach productivity and ongoing cost restructuring. Zacks' model predicts an earnings beat for MED, with a positive Earnings ESP and a Zacks Rank #3.
Medifast Inc (MED) Risk Assessment: Volatility, Financial Risk & Investment Risk
This article provides a risk assessment for Medifast Inc (MED), highlighting its current risk score of 5.66, ranking 46th in the Food & Tobacco industry. Key metrics such as the company's beta value of 0.65, maximum drawdown, and volatility are detailed. The analysis suggests that Medifast's stock tends to be less volatile than the broader market, experiencing smaller declines during downturns.
MED|Medifast Inc|Price:9.780|Chg%:-0.130
This article provides a comprehensive stock score analysis for Medifast Inc (MED), highlighting its healthy fundamentals and high growth potential despite a recent loss. The company is considered fairly valued within the Food & Tobacco industry and has high institutional ownership. Analysts currently rate the stock as "Hold" with a target price of $12.00.
Medifast Inc (MED) Q4 2025 Earnings Report - Results, Call & Slides
Medifast Inc (MED) has released its Q4 2025 earnings report, exceeding analyst expectations. The company reported an actual EPS of -$0.55 on revenue of $75.10M, beating consensus estimates of -$0.82 EPS and $71.40M revenue. Despite the beat, year-over-year revenue growth declined by 36.90%.
Medifast Inc (MED) Cash Flow
This article provides a detailed cash flow statement for Medifast Inc (MED), including operating, investing, and financing cash flows presented quarterly and annually. It highlights key financial figures such as operating cash flow of $6.86 million in FY2025 and capital expenditures of $5.61 million in the most recent quarter. The article also includes FAQs explaining different types of cash flow and their significance for investors.
Medifast (MED) to Release Quarterly Earnings on Monday
Medifast (MED) is scheduled to release its Q2 2026 earnings after market close on Monday, August 3rd, with analysts anticipating a loss of $0.67 per share on $72.7 million in revenue. The company had a stronger-than-expected Q1, reporting a $0.19 per-share loss against a $0.55 estimate, with revenue of $76.04 million. Medifast shares recently opened at $9.65, close to their 12-month low, and institutional investors hold 95.51% of the stock.
Lido Advisors LLC Decreases Stock Holdings in Medifast Inc $MED
Lido Advisors LLC significantly reduced its stake in Medifast Inc. (NYSE:MED) by 44.7% in the first quarter, now holding 183,035 shares valued at $1,865,000. Other institutional investors like BNP Paribas Financial Markets, Quantbot Technologies LP, Intesa Sanpaolo Wealth Management, State of Wyoming, and Strs Ohio also made changes, with most acquiring new stakes. Analyst ratings for Medifast are mixed, with an average "Hold" rating and a target price of $12.00, while the company recently reported exceeding earnings estimates but still has negative margins.
Medifast Inc (MED) Income Statement
This article provides Medifast Inc's (MED) income statement data, presenting both quarterly and annual financial metrics. It includes details such as total revenue, cost of revenue, operating expenses, operating profit, net non-operating interest, income before tax, income tax, income after tax, and earnings per share across multiple fiscal quarters and years. The content also answers frequently asked questions about understanding and analyzing Medifast Inc's income statement.
MED|Medifast Inc|Price:9.680|Chg%:+0.220
Medifast Inc. (MED) is a health and wellness company focusing on its OPTAVIA lifestyle solution, which includes coaching, community, tailored nutrition, and healthy habits to support weight management. The company also collaborates with LifeMD, Inc. to provide access to GLP-1 medications where appropriate. Its product line consists of approximately 79 consumable options sold under the OPTAVIA, OPTAVIA ACTIVE, and Optimal Health brands, and its stock traded at $9.680, up 2.33% at the close on July 24.
Medifast Inc (MED) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Medifast Inc (MED), highlighting its major shareholders and institutional holdings. It provides a breakdown of proportional ownership by investment advisors, hedge funds, and individual investors, along with a historical view of institutional shareholding and recent changes in holdings by key entities like BlackRock and Renaissance Technologies. The report also lists related ETFs that hold Medifast shares.
Medifast Inc (MED) Q1 2025 Earnings Report - Results, Call & Slides
Medifast Inc (MED) has released its Q1 2025 earnings report, revealing an actual EPS of -$0.58, significantly beating the consensus EPS of -$4.36. However, the company's actual revenue of $2.02 billion missed the expected revenue of $2.03 billion, marking a YoY revenue growth decrease of -33.77%. The next estimated earnings date for Medifast is August 3, 2026.
Medifast Inc (0K05) Q2 2025 Earnings Report - Results, Call & Slides
Medifast Inc (0K05) released its Q2 2025 earnings report, significantly beating both EPS and revenue expectations. The company reported actual EPS of $0.40 against a consensus of -$0.19, and actual revenue of $105.56 million compared to an expected $101.80 million. The earnings call and slide deck for Q2 2025 are available, and the next earnings date is estimated for August 3, 2026.
MED stock trades lower as Medifast returns to growth focus after TOP partnership reset
Medifast (MED) stock is trading lower as the company refocuses on a direct coach-led growth strategy following the termination of its partnership with The Optimal Health Partnership (TOP). The company reported an 11.6% revenue decline and a 44.7% drop in net income in Q1 2026, stemming from restructuring costs and lower sales volume. Despite these challenges, Medifast aims to stabilize revenue between $720 million and $760 million for the full year 2026, maintaining a stable gross margin as it rebuilds its OPTAVIA coach network and adapts to increasing competition from GLP-1 drugs.
Medifast to announce Q2 FY26 results on August 3
Medifast (NYSE: MED) will announce its financial results for the second quarter ended June 30, 2026, on Monday, August 3, 2026, after market close. A conference call featuring CEO Nick Johnson and CFO Jim Maloney will follow at 4:30 p.m. ET to discuss the results and provide further details. The webcast will be accessible via the company's investor relations website and archived until November 3, 2026.
Medifast launches Trilivy metabolic health system, unveils MetaVantage-enhanced Fuelings
Medifast announced the rebranding of its OPTAVIA program to Trilivy, launching a new comprehensive metabolic health system. The system introduces "Metabolic Synchronization" science, claiming significant visceral fat reduction, and includes the Trilivy Reset Fueling line with MetaVantage Technology. The program is structured in three phases (Reset, Refine, Renew) and maintains a coach-centric delivery model.
Medifast rebrands weight loss program as Trilivy
Medifast has rebranded its weight loss program as Trilivy, shifting its focus from solely weight loss to metabolic health. This move comes amid significant financial challenges for the company, including a 36% revenue decline, despite maintaining a strong gross profit margin. The new Trilivy system, incorporating "Metabolic Synchronization," aims to address metabolic dysfunction through new meal replacements and its established coach network.
Medifast launches Trilivy, replacing its Optavia brand
Medifast, Inc. (NYSE: MED) has launched Trilivy, its new metabolic health system, which replaces the former Optavia brand. This shift aims to broaden the company's focus from weight loss to comprehensive metabolic health, utilizing a science framework called Metabolic Synchronization. The system incorporates new meal replacements and a coach-supported program, aiming to address metabolic health challenges prevalent in over 90% of U.S. adults.
Medifast Gains on Trilivy Launch
Medifast, Inc. (NYSE: MED) has launched Trilivy, a comprehensive metabolic health system designed to support healthy lifestyle changes and optimize metabolism. This launch signifies a major corporate transformation for Medifast, moving beyond traditional weight loss to address broader metabolic health challenges. The company's stock saw a 1.5% increase following the announcement.
Medifast rebrands weight loss program as Trilivy
Medifast has rebranded its weight loss program to Trilivy, shifting its focus from solely weight loss to broader metabolic health. The new system, which includes reformulated meal replacements called Trilivy Reset Fueling line with MetaVantage Technology, aims to address metabolic dysfunction and preserve lean mass. This strategic change comes amidst financial challenges for Medifast, including declining revenue and leadership changes.
Medifast (NYSE: MED) rebrands OPTAVIA as Trilivy metabolic health platform
Medifast (NYSE: MED) has rebranded its OPTAVIA lifestyle brand as Trilivy, a comprehensive metabolic health system focusing on broader metabolic health rather than just weight loss. The Trilivy system is built around "Metabolic Synchronization" and involves three phases: Reset, Refine, and Renew, supported by new "Trilivy Reset Fuelings" with MetaVantage Technology and a network of independent coaches. Clinical research cited by the company suggests significant reductions in visceral fat and retention of lean mass, with coach-supported programs demonstrating greater weight and fat loss.
Medifast Enters a New Era: Introducing Trilivy, a Science-Backed Metabolic Health System
Medifast has launched Trilivy, a new comprehensive metabolic health system marking its transformation from a weight loss company to one focused on optimal metabolic health. Trilivy features new meal replacements with MetaVantage Technology™ and is designed to reverse metabolic dysfunction through Metabolic Synchronization®, emphasizing fat burning, lean mass preservation, and healthy metabolism support with a three-phase system and coach support. This initiative aims to address widespread metabolic health challenges and expand Medifast's vision beyond traditional weight loss.
Medifast (NYSE:MED) Upgraded by Zacks Research to Strong-Buy Rating
Zacks Research has upgraded Medifast (NYSE:MED) from a "hold" to a "strong-buy" rating. Despite this, the broader analyst consensus for Medifast remains a "Hold" with an average target price of $12.00, and the stock recently traded below its 50-day and 200-day moving averages. The company recently exceeded earnings and revenue estimates but guided for continued losses in FY2026 and Q2 2026.
